Tasly Pharmaceutical Reports H1 2026 Net Profit Attributable to Shareholders of RMB893 Million, Up 15.23%

Stock News07-14

According to a corporate announcement, CHINARES PHARMA (03320) disclosed the financial results for Tasly Pharmaceutical Group Co.,Ltd. for the first half of 2026.

The company reported operating revenue of RMB4.201 billion, representing a year-on-year decrease of 2.03%. This decline was primarily attributed to an overall downturn in the traditional Chinese medicine injection sector and a reduction in sales revenue from cold and fever medications compared to the same period last year.

Net profit attributable to shareholders of the listed company reached RMB893 million, marking a 15.23% increase compared to the prior year period.

Adjusted net profit attributable to shareholders, which excludes non-recurring gains and losses, amounted to RMB871 million, reflecting a significant year-on-year growth of 36.01%.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1180842177?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-14 19:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1180842177","market":"us","top_or_hot":-1,"title":"Tasly Pharmaceutical Reports H1 2026 Net Profit Attributable to Shareholders of RMB893 Million, Up 15.23%","media":"Stock News","content":"<p>According to a corporate announcement, <b>CHINARES PHARMA</b> (<b>03320</b>) disclosed the financial results for <b>Tasly Pharmaceutical Group Co.,Ltd.</b> for the first half of 2026.<br><br>The company reported operating revenue of RMB4.201 billion, representing a year-on-year decrease of 2.03%. This decline was primarily attributed to an overall downturn in the traditional Chinese medicine injection sector and a reduction in sales revenue from cold and fever medications compared to the same period last year.<br><br>Net profit attributable to shareholders of the listed company reached RMB893 million, marking a 15.23% increase compared to the prior year period.<br><br>Adjusted net profit attributable to shareholders, which excludes non-recurring gains and losses, amounted to RMB871 million, reflecting a significant year-on-year growth of 36.01%.<br><br></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tasly Pharmaceutical Reports H1 2026 Net Profit Attributable to Shareholders of RMB893 Million, Up 15.23%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTasly Pharmaceutical Reports H1 2026 Net Profit Attributable to Shareholders of RMB893 Million, Up 15.23%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-14 19:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>According to a corporate announcement, <b>CHINARES PHARMA</b> (<b>03320</b>) disclosed the financial results for <b>Tasly Pharmaceutical Group Co.,Ltd.</b> for the first half of 2026.<br><br>The company reported operating revenue of RMB4.201 billion, representing a year-on-year decrease of 2.03%. This decline was primarily attributed to an overall downturn in the traditional Chinese medicine injection sector and a reduction in sales revenue from cold and fever medications compared to the same period last year.<br><br>Net profit attributable to shareholders of the listed company reached RMB893 million, marking a 15.23% increase compared to the prior year period.<br><br>Adjusted net profit attributable to shareholders, which excludes non-recurring gains and losses, amounted to RMB871 million, reflecting a significant year-on-year growth of 36.01%.<br><br></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"","article_id":"1180842177","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1180842177","pubTimestamp":1784029344,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"According to a corporate announcement, CHINARES PHARMA (03320) disclosed the financial results for Tasly Pharmaceutical Group Co.,Ltd. for the first half of 2026.The company reported operating...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","600535":"天士力","BK1574":"生物医药B类股","03320":"华润医药","BK1161":"生物科技","BK0239":"医药制造","BK0196":"行业龙头","BK0183":"MSCI概念","BK1191":"制药","BK1515":"抗疫概念","BK0188":"融资融券","BK0028":"国家队","BK1570":"华润系","BK0012":"证金概念","09939":"开拓药业-B"},"translate_title":"天士力医药2026年上半年股东应占净利润为人民币8.93亿元，同比增长15.23%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"600535":1,"09939":1,"03320":1},"content_text":"According to a corporate announcement, CHINARES PHARMA (03320) disclosed the financial results for Tasly Pharmaceutical Group Co.,Ltd. for the first half of 2026.The company reported operating revenue of RMB4.201 billion, representing a year-on-year decrease of 2.03%. This decline was primarily attributed to an overall downturn in the traditional Chinese medicine injection sector and a reduction in sales revenue from cold and fever medications compared to the same period last year.Net profit attributable to shareholders of the listed company reached RMB893 million, marking a 15.23% increase compared to the prior year period.Adjusted net profit attributable to shareholders, which excludes non-recurring gains and losses, amounted to RMB871 million, reflecting a significant year-on-year growth of 36.01%.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1180842177","isCrawlerRequest":true}